Physician profile

Robert D Moore

Surgery · North Andover, MA

NPI 1346296548

$466.35

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$248.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $130.88 2023 Signia
Becton, Dickinson and Company $99.06 2024 Phasix Mesh
Tela Bio, INC. $56.24 2019-2024 Ovitex 2s
Kci USA, INC. $49.60 2019
Genentech USA, INC. $34.07 2019
Pacira Pharmaceuticals Incorporated $21.10 2019
Zimmer Biomet Holdings, INC. $19.23 2019
Ethicon US, LLC $15.62 2019
Acell, INC. $14.31 2019
Convatec INC. $14.24 2019
Smith+Nephew, INC. $12.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert D Moore

$466.35

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/1198599/robert-d-moore

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.